血液学の最新論文（2020年3月前半リリース分）New reports on Hematology
Leukemia
- Blood An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. 2020 Mar 10. pii: blood.2020004834. doi: 10.1182/blood.2020004834. Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S, Soh SX, Heng XT, Takahashi N, Tan JHJ, Bhatia R, Khng AJ, Chng WJ, Sia YY, Fruman DA, Ng KP, Chan ZE, Xie KJ, Hoi Q, Chan CX, Teo ASM, Velazquez O, Meah WY, Khor CC, Ong CT, Soon WW, Tan P, Ng PC, Chuah C, Hillmer AM, Ong ST
- Blood Evolution of retrovirus-infected premalignant T-cell clones prior to Adult T-cell leukemia/lymphoma diagnosis. Blood. 2020 Mar 5. pii: blood.2019002665. doi: 10.1182/blood.2019002665. Rowan AG, Dillon R, Witkover A, Melamed A, Demontis MA, Gillet NA, Mun LJ, Bangham CRM, Cook LB, Fields PA, Taylor GP
- Blood BCL-2 inhibition and AML: can we best Darwin? 135(11):781-782 Michaelis LC
- Blood Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. 135(11):791-803 DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH
- Blood How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. 135(11):804-813 Aldoss I, Forman SJ
- Blood High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. 135(11):866-870 Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, Tandon M, Jiang Y, Schary W, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer KA
- Blood Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. 135(11):870-875 Bezerra MF, Lima AS, Piqué-Borràs MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, Weinhäuser I, Franca-Neto PL, Quek L, Corby A, Oliveira MM, Lima MM, de Assis RA, de Melo Campos P, Duarte BK, Bendit I, Rocha V, Rego EM, Traina F, Saad ST, Beltrão EI, Bezerra MA, Lucena-Araujo AR
- Blood Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia. 135(11):880 Liu W, Xu J
- Blood A bispecific approach to improving CAR T cells in AML. 135(10):703-704 Daver N
- Blood Breaking through BCL-2 inhibition in CLL. 135(10):709-711 Chong SJF, Davids MS
- Blood Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. 135(10):713-723 He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O'Dwyer KP, Siegel DL, June CH, Hua X
- Blood Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML. 135(10):766-769 Gottschalk A, Glauche I, Cicconi S, Clark RE, Roeder I
- Blood Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. 135(10):773-777 Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, McBean M, Thijssen R, Conway T, Anderson MA, Seymour JF, Westerman DA, Czabotar PE, Huang DCS, Roberts AW
- Br J Haematol Current pricing model for cancer drugs – is it ‘Justum Pretium’ for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16564. Varghese AM, Sood N, Daniel SM
- Br J Haematol Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Br J Haematol. 2020 Mar 5. doi: 10.1111/bjh.16456. Ladikou EE, Chevassut T, Pepper CJ, Pepper AG
- Br J Haematol Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1. Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16530. LeBlanc FR, Pearson JM, Tan SF, Cheon H, Xing JC, Dunton W, Feith DJ, Loughran TP Jr
- Br J Haematol Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16420. Prieto-Conde MI, Jiménez C, García-Álvarez M, Ramos F, Medina A, Cuello R, Balanzategui A, Alonso JM, Sarasquete ME, Queizán JA, Alcoceba M, Bárez A, Puig N, Cantalapiedra A, Gutiérrez NC, García-Sanz R, González-Díaz M, Chillón MC
- Br J Haematol Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16540. Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Br J Haematol Mutant allelic burden in acute myeloid leukaemia: Why bother? 188(6):817-818 Touw IP, Sanders MA
- Br J Haematol Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. 188(6):844-851 Gribben JG
- Br J Haematol Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. 188(6):852-859 Linch DC, Hills RK, Burnett AK, Russell N, Gale RE
- Br J Haematol Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL. 188(6):872-880 Elston L, Fegan C, Hills R, Hashimdeen SS, Walsby E, Henley P, Pepper C, Man S
- Br J Haematol Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. 188(6):881-887 Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A
- Br J Haematol The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. 188(6):918-923 Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR
- Br J Haematol Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. 188(6):945-961 Zhou C, Zhuang Y, Lin X, Michelson AD, Zhang A
- Br J Haematol Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia. 188(5):599 Richardson AI, Skikne BS, Woodroof J
- Br J Haematol Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. 188(5):605-622 Palomo L, Ibáñez M, Abáigar M, Vázquez I, Álvarez S, Cabezón M, Tazón-Vega B, Rapado I, Fuster-Tormo F, Cervera J, Benito R, Larrayoz MJ, Cigudosa JC, Zamora L, Valcárcel D, Cedena MT, Acha P, Hernández-Sánchez JM, Fernández-Mercado M, Sanz G, Hernández-Rivas JM, Calasanz MJ, Solé F, Such E; Spanish Group of MDS (GESMD)
- Br J Haematol Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia. 188(5):652-660 Chin-Yee B, Sadikovic B, Chin-Yee IH
- Br J Haematol Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. 188(5):674-684 Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H
- Br J Haematol Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children. 188(5):701-706 Knöfler R, Lange BS, Paul F, Tiebel O, Suttorp M
- Br J Haematol TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia. 188(5):736-739 Cucchi DGJ, Bachas C, Klein K, Huttenhuis S, Zwaan CM, Ossenkoppele GJ, Janssen JMWM, Kaspers GL, Cloos J
- Br J Haematol Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients. 188(5):740-744 Kim YA, Ju HY, Park HJ, Lee NY, Lee HJ, Lee H, Ghang H
- Br J Haematol Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. 188(5):757-767 Xue YJ, Suo P, Huang XJ, Lu AD, Wang Y, Zuo YX, Yan CH, Wu J, Kong J, Zhang XH, Chen YH, Jia YP, Liu KY, Han W, Xu LP, Zhang LP, Cheng YF
- Haematologica The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2020 Mar 12. pii: haematol.2019.233445. doi: 10.3324/haematol.2019.233445. Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y
- Haematologica P2X7 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3. Haematologica. 2020 Mar 12. pii: haematol.2019.243360. doi: 10.3324/haematol.2019.243360. Feng W, Yang X, Wang L, Wang R, Yang F, Wang H, Liu X, Ren Q, Zhang Y, Zhu X, Zheng G
- Haematologica Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica. 2020 Mar 5. pii: haematol.2019.238154. doi: 10.3324/haematol.2019.238154. Hanna BS, Yazdanparast H, Demerdash Y, Roessner PM, Schulz R, Lichter P, Stilgenbauer S, Seiffert M
- Haematologica Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica. 2020 Mar 5. pii: haematol.2019.241026. doi: 10.3324/haematol.2019.241026. Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW
- Haematologica 100-Year Old Haematologica Images: Di Guglielmo Disease or Pure Erythroid Leukemia. 105(3):525 Balduini CL
- Haematologica Are next-generation sequencing results knocking on Heaven’s door for transplantation planning in chronic myelomonocytic leukemia? 105(3):530-533 Sanz GF, Ibañez M, Mora E
- Haematologica Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification. 105(3):533-536 Knorr KLB, Goldberg AD
- Haematologica Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. 105(3):652-660 Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ
- Haematologica Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish. 105(3):674-686 Xu M, Ye Y, Ye Z, Xu S, Liu W, Xu J, Zhang Y, Liu Q, Huang Z, Zhang W
- Haematologica The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. 105(3):687-696 Annageldiyev C, Gowda K, Patel T, Bhattacharya P, Tan SF, Iyer S, Desai D, Dovat S, Feith DJ, Loughran TP Jr, Amin S, Claxton D, Sharma A
- Haematologica Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. 105(3):697-707 Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M
- Haematologica Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. 105(3):708-720 Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA
- Haematologica Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. 105(3):721-729 Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrózek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD
- Haematologica Progression of progenitor B-cell leukemia is associated with alterations of the bone marrow micro-environment. 105(3):e102-e106 Åhsberg J, Xiao P, Okuyama K, Somasundaram R, Strid T, Qian H, Sigvardsson M
- J Clin Oncol Less Is Not Necessarily More: Toward a Rational Selection of the Conditioning Regimen in Acute Myeloid Leukemia. J Clin Oncol. 2020 Mar 2:JCO1903161. doi: 10.1200/JCO.19.03161. Freeman S, Craddock C
- J Clin Oncol Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. 38(7):715-724 Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM
- Lancet Haematol First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an “operational cure”. 7(3):e182-e183 Breccia M, Foà R
- Lancet Haematol Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. 7(3):e218-e225 Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y; DADI Trial Group
- Lancet Haematol Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. 7(3):e238-e246 Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A
- Lancet Haematol Plasma cell leukaemia presenting as flower-shaped plasma cells mimicking adult T-cell leukaemia or lymphoma. 7(3):e270 Shibusawa M
- Lancet Oncol Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020 Mar 11. pii: S1470-2045(20)30060-7. doi: 10.1016/S1470-2045(20)30060-7. Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, Opferman JT, Rubnitz JE
- Lancet Oncol Venetoclax for paediatric acute myeloid leukaemia: a step forward. Lancet Oncol. 2020 Mar 11. pii: S1470-2045(20)30136-4. doi: 10.1016/S1470-2045(20)30136-4. Aplenc R
- Lancet Oncol Trafficking of CAR T cells to sites of subclinical leukaemia cutis. 21(3):e179 O'Reilly M, Roddie C, Marzolini MAV, Rodriguez-Justo M, Pomplun S, Pule M, Peggs KS
- Leukemia UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia. 2020 Mar 9. doi: 10.1038/s41375-020-0784-2. Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group
- Leukemia Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Mar 4. doi: 10.1038/s41375-020-0783-3. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM
- Leukemia Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant? Leukemia. 2020 Mar 4. doi: 10.1038/s41375-020-0780-6. Venditti A, Peter Gale R, Buccisano F, Ossenkoppele G
- Leukemia Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0762-8. Arindrarto W, Borràs DM, de Groen RAL, van den Berg RR, Locher IJ, van Diessen SAME, van der Holst R, van der Meijden ED, Honders MW, de Leeuw RH, Verlaat W, Jedema I, Kroes WGM, Knijnenburg J, van Wezel T, Vermaat JSP, Valk PJM, Janssen B, de Knijff P, van Bergen CAM, van den Akker EB, Hoen PAC', Kiełbasa SM, Laros JFJ, Griffioen M, Veelken H
- Leukemia European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0776-2. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R
- Leukemia Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0779-z. Horak P, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C, Glimm H
- Leukemia Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? 34(3):671-681 Estey E, Karp JE, Emadi A, Othus M, Gale RP
- Leukemia FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. 34(3):682-696 Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A
- Leukemia CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. 34(3):709-720 Leung KT, Zhang C, Chan KYY, Li K, Cheung JTK, Ng MHL, Zhang XB, Sit T, Lee WYW, Kang W, To KF, Yu JWS, Man TKF, Wang H, Tsang KS, Cheng FWT, Lam GKS, Chow TW, Leung AWK, Leung TF, Yuen PMP, Ng PC, Li CK
- Leukemia Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. 34(3):721-734 Vorbach S, Gründer A, Zhou F, Koellerer C, Jutzi JS, Simoni M, Riccetti L, Valk PJ, Sanders MA, Müller-Tidow C, Nofer JR, Pahl HL, Potì F
- Leukemia A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. 34(3):735-745 Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK
- Leukemia Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. 34(3):759-770 Saida S, Zhen T, Kim E, Yu K, Lopez G, McReynolds LJ, Liu PP
- Leukemia Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. 34(3):787-798 Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ
- Leukemia Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia. 34(3):811-820 Hartmann L, Nadarajah N, Meggendorfer M, Höllein A, Vetro C, Kern W, Haferlach T, Haferlach C, Stengel A
- Leukemia Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15R138C knock-in mice. 34(3):882-894 Tatsumi G, Kawahara M, Imai T, Nishishita-Asai A, Nishida A, Inatomi O, Yokoyama A, Kakuta Y, Kito K, Andoh A
- Leukemia HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. 34(3):909-913 Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, Xiao X, Jiang Y, Li Q, Zhang H, Lu W, Lyu C, Jiang Y, Meng J, Zhao M
- Leukemia Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. 34(3):914-918 Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F
- Leukemia Circ-RPL15: a plasma circular RNA as novel oncogenic driver to promote progression of chronic lymphocytic leukemia. 34(3):919-923 Wu Z, Sun H, Liu W, Zhu H, Fu J, Yang C, Fan L, Wang L, Liu Y, Xu W, Li J, Jin H
- Leukemia Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. 34(3):924-928 Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B
- Leukemia In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. 34(3):929-931 Baccarani M, Iacobucci I, Chiaretti S, Foà' R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, Coriu D, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Poopak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibali O, Crugnola M, Passamonti F
- Leukemia PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. 34(3):932-937 Tumino N, Besi F, Di Pace AL, Mariotti FR, Merli P, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P
- Leukemia Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. 34(3):957-962 Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Saunthararajah Y, Carraway H, Sekeres M, Maciejewski JP
Lymphoma
- Blood Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral directed immunotherapy. Blood. 2020 Mar 10. pii: blood.2019004126. doi: 10.1182/blood.2019004126. Dalton T, Doubrovina E, Pankov D, Reynolds RC, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C, Oakes CC, Alonso A, Elemento O, Pan H, Phillip JM, O'Reilly RJ, Gewurz BE, Cesarman E, Giulino-Roth L
- Blood Evolution of retrovirus-infected premalignant T-cell clones prior to Adult T-cell leukemia/lymphoma diagnosis. Blood. 2020 Mar 5. pii: blood.2019002665. doi: 10.1182/blood.2019002665. Rowan AG, Dillon R, Witkover A, Melamed A, Demontis MA, Gillet NA, Mun LJ, Bangham CRM, Cook LB, Fields PA, Taylor GP
- Blood Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020 Mar 5. pii: blood.2019002385. doi: 10.1182/blood.2019002385. Pararajalingam P, Coyle KM, Arthur S, Thomas N, Alcaide M, Meissner B, Boyle M, Qureshi Q, Grande BM, Rushton C, Slack GW, Mungall A, Tam C, Agarwal R, Dawson SJ, Lenz G, Balasubramanian S, Gascoyne RD, Steidl C, Connors J, Villa D, Audas TE, Marra MA, Johnson NA, Scott DW, Morin RD
- Blood Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood. 2020 Mar 2. pii: blood.2019003073. doi: 10.1182/blood.2019003073. Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, Houillier C, Hoang-Xuan K, Gyan E, Le Lez ML, Lavaud A, Soubeyran P, Bodaghi B, Costopoulos M, Leblond V, Touitou V, Maloum K, Errera MH, Roos-Weil D, Le Garff-Tavernier M, Choquet S
- Blood IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. 135(11):834-844 Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben JG, Forconi F, Stevenson FK, Calaminici M, Krysov S
- Blood Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. 135(11):862-865 Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P
- Blood CD45-negative follicular lymphoma. 135(11):879 Schoonen L, Weerkamp F
- Blood Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. 135(10):735-742 Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A
- Blood Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen. 135(10):778 Fu CL, Diacovo MJ
- Br J Haematol The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16555. Bishton MJ, Rule S, Wilson W, Turner D, Patmore R, Clifton-Hadley L, McMillan A, Lush R, Haynes A
- Br J Haematol Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16563. D'Alò F, Malafronte R, Piludu F, Bellesi S, Cuccaro A, Maiolo E, Modoni A, Leccisotti L, Macis G, Mores N, De Stefano V, Hohaus S
- Br J Haematol Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16567. Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Böhmer LH, Minnema MC, MacKenzie MA, van Marwijk Kooij R, de Jongh E, Snijders TJF, de Weerdt O, van Gelder M, Hoogendoorn M, Leys RBL, Kibbelaar RE, de Jong D, Chitu DA, Van't Veer MB, Kluin-Nelemans HC
- Br J Haematol Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020 Mar 6. doi: 10.1111/bjh.16461. Moleti ML, Testi AM, Foà R
- Br J Haematol Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol. 2020 Mar 5. doi: 10.1111/bjh.16541. Imber BS, Sadelain M, DeSelm C, Batlevi C, Brentjens RJ, Dahi PB, Giralt S, Park JH, Sauter C, Scordo M, Shah G, Perales MA, Palomba ML, Yahalom J
- Br J Haematol Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. Br J Haematol. 2020 Mar 4. doi: 10.1111/bjh.16474. López-Díaz de Cerio A, García-Muñoz R, Pena E, Panizo Á, Feliu J, Giraldo P, Rodríguez-Calvillo M, Martínez-Calle N, Grande C, Olave MT, Andrade-Campos M, Bandrés E, Núñez-Córdoba JM, Inogés S, Panizo C
- Br J Haematol Bone marrow involvement by nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16464. Parsons KE, Goodlad JR, Leach M
- Br J Haematol What do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options. 188(6):831-837 Duffles Amarante G, Collins G, Rocha V
- Br J Haematol Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. 188(6):860-871 Jeon YW, O JH, Park KS, Min GJ, Park SS, Yoon JH, Eom KS, Min CK, Cho SG
- Br J Haematol New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). 188(6):888-897 Bento L, Díaz-López A, Barranco G, Martín-Moreno AM, Baile M, Martín A, Sancho JM, García O, Rodríguez M, Sánchez-Pina JM, Novelli S, Salar A, Bastos M, Rodríguez-Salazar MJ, González de Villambrosia S, Córdoba R, García-Recio M, Martínez-Serra J, Del Campo R, Luzardo H, García D, Hong A, Abrisqueta P, Sastre-Serra J, Roca P, Rodríguez J, Gutiérrez A; Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO)
- Br J Haematol First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. 188(6):898-906 Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, Giza A, Zaucha JM, Kalinka-Warzocha E, Wieczorkiewicz A, Zimowska-Curyło D, Knopińska-Posłuszny W, Tyczyńska A, Romejko-Jarosińska J, Dąbrowska-Iwanicka A, Gruszecka B, Jamrozek-Jedlińska M, Borawska A, Hołda W, Porowska A, Romanowicz A, Hellmann A, Stella-Hołowiecka B, Deptała A, Jurczak W
- Br J Haematol Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. 188(6):930-934 Korula A, Devasia AJ, Kulkarni U, Abubacker FN, Lakshmi KM, Abraham A, Srivastava A, George B, Mathews V
- Br J Haematol Who is the best relative? Optimizing haploidentical donor transplantation in lymphoma. 188(5):601-602 Kanate AS, Savani BN
- Br J Haematol Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. 188(5):661-673 García-Muñoz R, Quero C, Pérez-Persona E, Domingo-García A, Pérez-López C, Villaescusa-de-la-Rosa T, Martínez-Castro AM, Arguiñano-Pérez JM, Parra-Cuadrado JF, Panizo C
- Br J Haematol No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. 188(5):685-691 Lagerlöf I, Holte H, Glimelius I, Björkholm M, Enblad G, Erlanson M, Fluge Ø, Fohlin H, Fosså A, Goldkuhl C, Gustavsson A, Johansson AS, Linderoth J, Nome O, Palma M, Åkesson L, Østenstad B, Raud C, Glimelius B, Molin D
- Br J Haematol Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. 188(5):745-756 Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A
- Haematologica CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion. 105(3):730-740 Martín-Cortázar C, Chiodo Y, Jiménez RP, Bernabé M, Cayuela ML, Iglesias T, Campanero MR
- Haematologica A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. 105(3):741-753 Falgàs A, Pallarès V, Unzueta U, Céspedes MV, Arroyo-Solera I, Moreno MJ, Sierra J, Gallardo A, Mangues MA, Vázquez E, Villaverde A, Mangues R, Casanova I
- Haematologica Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. 105(3):754-764 Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I, Fend F, Quintanilla-Martinez L
- Haematologica Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo. 105(3):796-807 Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N
- Haematologica Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. 105(3):e107-e110 Li Z, Song Y, Zhang Y, Li C, Wang Y, Xue W, Lu L, Jin M, Zhou Z, Wang X, Li L, Zhang L, Li X, Fu X, Sun Z, Wu J, Zhang X, Yu H, Nan F, Chang Y, Yan J, Feng X, Wu X, Wang G, Zhang D, Li W, Li F, Zhang Y, Young KH, Zhang M
- J Clin Oncol Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. 38(7):662-668 Bartlett NL
- J Clin Oncol Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. 38(7):698-705 Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A
- Lancet Haematol Cardio-oncology for better lymphoma therapy outcomes. Lancet Haematol. 2020 Mar 2. pii: S2352-3026(20)30066-1. doi: 10.1016/S2352-3026(20)30066-1. Jurczak W, Długosz-Danecka M, Szmit S
- Lancet Haematol Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020 Mar 2. pii: S2352-3026(20)30031-4. doi: 10.1016/S2352-3026(20)30031-4. Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW
- Lancet Haematol Plasma cell leukaemia presenting as flower-shaped plasma cells mimicking adult T-cell leukaemia or lymphoma. 7(3):e270 Shibusawa M
- Lancet Oncol Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Mar 11. pii: S1470-2045(20)30059-0. doi: 10.1016/S1470-2045(20)30059-0. Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T
- Leukemia Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2020 Mar 9. doi: 10.1038/s41375-020-0791-3. Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, Zhang LL, Wu G, Qu BL, Qian LT, Hou XR, Zhang FQ, Qiao XY, Wang H, Li GF, Zhang YJ, Zhu Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, Shi M, Xu LM, Yuan ZY, Yahalom J, Tsang R, Song YQ, Zhu J, Su H, Li YX
- Leukemia The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK- anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia. 2020 Mar 2. doi: 10.1038/s41375-020-0754-8. Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, Iqbal J, Wang R, Fiore D, Mularoni V, Chan WC, Lhoumaud P, Skok J, Zanetti E, Merli F, Ciarrocchi A, Elemento O, Inghirami G
- Leukemia ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. 34(3):771-786 Riabinska A, Lehrmann D, Jachimowicz RD, Knittel G, Fritz C, Schmitt A, Geyer A, Heneweer C, Wittersheim M, Frenzel LP, Torgovnick A, Wiederstein JL, Wunderlich CM, Ortmann M, Paillard A, Wößmann W, Borkhardt A, Burdach S, Hansmann ML, Rosenwald A, Perner S, Mall G, Klapper W, Merseburg A, Krüger M, Grüll H, Persigehl T, Wunderlich FT, Peifer M, Utermöhlen O, Büttner R, Beleggia F, Reinhardt HC
- Leukemia Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. 34(3):787-798 Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ
- Leukemia T cells redirected against Igβ for the immunotherapy of B cell lymphoma. 34(3):821-830 Jiang D, Tian X, Bian X, Zhu T, Qin H, Zhang R, Xu Y, Pan Z, Huang H, Fu J, Wu D, Chu J
- Leukemia Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. 34(3):845-856 Kamijo H, Miyagaki T, Takahashi-Shishido N, Nakajima R, Oka T, Suga H, Sugaya M, Sato S
- Leukemia Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. 34(3):857-871 Gehringer F, Weissinger SE, Möller P, Wirth T, Ushmorov A
- Leukemia Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma. 34(3):947-952 Adams CM, Mitra R, Vogel AN, Liu J, Gong JZ, Eischen CM
- Leukemia Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. 34(3):953-956 Eichenauer DA, Plütschow A, Fuchs M, Hartmann S, Hansmann ML, Böll B, von Tresckow B, Borchmann P, Engert A
Myeloma
- Br J Haematol Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway. Br J Haematol. 2020 Mar 13. doi: 10.1111/bjh.16477. Wang H, Gong Y, Liang L, Xiao L, Yi H, Ye M, Roy M, Xia J, Zhou W, Yang C, Shen X, Zhang B, Li Z, Liu J, Zhou H, Xiao X
- Br J Haematol Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. Br J Haematol. 2020 Mar 12. doi: 10.1111/bjh.16572. Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, Minařík J, Pavlíček P, Radocha J, Heindorfer A, Jelínek T, Stejskal L, Brožová L, Ševčíková S, Straub J, Pika T, Pour L, Maisnar V, Seckinger A, Hose D
- Br J Haematol CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy. Br J Haematol. 2020 Mar 12. doi: 10.1111/bjh.16548. Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N
- Br J Haematol The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells. Br J Haematol. 2020 Mar 10. doi: 10.1111/bjh.16569. Wu X, Guo J, Chen Y, Liu X, Yang G, Wu Y, Tian Y, Liu N, Yang L, Wei S, Deng H, Chen W
- Br J Haematol Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow. Br J Haematol. 2020 Mar 4. doi: 10.1111/bjh.16547. Petrackova A, Minarik J, Sedlarikova L, Libigerova T, Hamplova A, Krhovska P, Balcarkova J, Pika T, Papajik T, Kriegova E
- Br J Haematol Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16550. Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A
- Br J Haematol Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. 188(6):907-917 Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, Patriarca F, Gherlinzoni F, Zambello R, Sammassimo S, Marcatti M, Nozza A, Crippa C, Cafro AM, Baldini L, Corradini P
- Br J Haematol Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. 188(5):692-700 Chan HSH, Milne RJ
- Br J Haematol An upsurge of the serum free light chains as a possible missing link in tumour lysis syndrome in multiple myeloma. 188(5):732-735 Yavorkovsky LL, Jing W, Baker R
- Haematologica The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. 105(3):774-783 Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G
- Haematologica Kinome expression profiling to target new therapeutic avenues in multiple myeloma. 105(3):784-795 de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J
- Haematologica Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. 105(3):e111-e115 Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S
- Haematologica Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. 105(3):e116-e120 Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM
- Haematologica Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. 105(3):e138-e140 Kovacs SB, Luan J, Dold SM, Weis A, Pantic M, Duyster J, Wäsch R, Engelhardt M
- Haematologica Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). 105(3):e141-e143 Swan D, Delaney C, Natoni A, O'Dwyer M, Krawczyk J
- J Clin Oncol Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. J Clin Oncol. 2020 Mar 11:JCO1902972. doi: 10.1200/JCO.19.02972. Biran N, Vesole DH, Donato ML, Ip A, Kaur G, Goldberg S, Siegel DS
- J Clin Oncol Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. 38(8):775-783 Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H
- J Clin Oncol Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. 38(8):784-792 Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group
- Lancet Haematol MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 Mar 11. pii: S2352-3026(19)30249-2. doi: 10.1016/S2352-3026(19)30249-2. Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M
- Lancet Haematol Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? Lancet Haematol. 2020 Mar 11. pii: S2352-3026(19)30254-6. doi: 10.1016/S2352-3026(19)30254-6. D'Agostino M, Mina R, Gay F
- Leukemia Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia. 2020 Mar 11. doi: 10.1038/s41375-020-0750-z. Shah V, Sherborne AL, Johnson DC, Ellis S, Price A, Chowdhury F, Kendall J, Jenner MW, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Davies FE, Cook G, Cairns DA, Houlston RS, Jackson G, Kaiser MF; on behalf of NCRI Haematology Clinical Studies Group
- Leukemia Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia. 2020 Mar 2. doi: 10.1038/s41375-020-0785-1. Sarin V, Yu K, Ferguson ID, Gugliemini O, Nix MA, Hann B, Sirota M, Wiita AP
- Leukemia Genetic predisposition for multiple myeloma. 34(3):697-708 Pertesi M, Went M, Hansson M, Hemminki K, Houlston RS, Nilsson B
- Leukemia DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. 34(3):938-941 Choudhry P, Mariano MC, Geng H, Martin TG 3rd, Wolf JL, Wong SW, Shah N, Wiita AP
SCT
- Br J Haematol Fungal infections in children with haematologic malignancies and stem cell transplant recipients. Br J Haematol. 2020 Mar 11. doi: 10.1111/bjh.16452. Otto WR, Green AM
- Br J Haematol Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 Mar 10. doi: 10.1111/bjh.16552. Richardson PG, Smith AR, Kernan NA, Lehmann L, Soiffer RJ, Ryan RJ, Tappe W, Grupp S
- Br J Haematol Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16567. Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Böhmer LH, Minnema MC, MacKenzie MA, van Marwijk Kooij R, de Jongh E, Snijders TJF, de Weerdt O, van Gelder M, Hoogendoorn M, Leys RBL, Kibbelaar RE, de Jong D, Chitu DA, Van't Veer MB, Kluin-Nelemans HC
- Br J Haematol Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol. 2020 Mar 4. doi: 10.1111/bjh.16557. Cairo MS, Cooke KR, Lazarus HM, Chao N
- Br J Haematol Paediatric haematologists’ attitudes regarding haematopoietic cell transplantation as treatment for sickle cell disease. 188(6):976-984 Stallings AM, Majhail NS, Nowacki AS, Onimoe GI, Hanna R, Piccone CM
- Br J Haematol Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. 188(5):745-756 Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A
- Br J Haematol Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. 188(5):757-767 Xue YJ, Suo P, Huang XJ, Lu AD, Wang Y, Zuo YX, Yan CH, Wu J, Kong J, Zhang XH, Chen YH, Jia YP, Liu KY, Han W, Xu LP, Zhang LP, Cheng YF
- Br J Haematol GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner. 188(5):768-773 Bogaert DJ, Laureys G, Naesens L, Mazure D, De Bruyne M, Hsu AP, Bordon V, Wouters E, Tavernier SJ, Lambrecht BN, De Baere E, Haerynck F, Kerre T
- Haematologica CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation. Haematologica. 2020 Mar 12. pii: haematol.2019.244152. doi: 10.3324/haematol.2019.244152. Kalin B, Metafuni E, Ter Borg M, Wijers R, Braakman E, Lamers CHJ, Bacigalupo A, Cornelissen JJ
- Lancet Haematol Imaging haemopoietic stem cells and microenvironment dynamics through transplantation. 7(3):e259-e269 Williams KM, Chakrabarty JH
- Leukemia Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study. 34(3):831-844 Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF
- Leukemia HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. 34(3):909-913 Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, Xiao X, Jiang Y, Li Q, Zhang H, Lu W, Lyu C, Jiang Y, Meng J, Zhao M
- Leukemia PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. 34(3):932-937 Tumino N, Besi F, Di Pace AL, Mariotti FR, Merli P, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P
HSC
- Br J Haematol Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. 188(5):757-767 Xue YJ, Suo P, Huang XJ, Lu AD, Wang Y, Zuo YX, Yan CH, Wu J, Kong J, Zhang XH, Chen YH, Jia YP, Liu KY, Han W, Xu LP, Zhang LP, Cheng YF
- Br J Haematol GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner. 188(5):768-773 Bogaert DJ, Laureys G, Naesens L, Mazure D, De Bruyne M, Hsu AP, Bordon V, Wouters E, Tavernier SJ, Lambrecht BN, De Baere E, Haerynck F, Kerre T
- Haematologica CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation. Haematologica. 2020 Mar 12. pii: haematol.2019.244152. doi: 10.3324/haematol.2019.244152. Kalin B, Metafuni E, Ter Borg M, Wijers R, Braakman E, Lamers CHJ, Bacigalupo A, Cornelissen JJ
- Haematologica Genetic fingerprint defines hematopoietic stem cell pool size and function. 105(3):526-528 Morishima T, Takizawa H
- Haematologica Latexin regulation by HMGB2 is required for hematopoietic stem cell maintenance. 105(3):573-584 Zhang C, Fondufe-Mittendorf YN, Wang C, Chen J, Cheng Q, Zhou D, Zheng Y, Geiger H, Liang Y
- Lancet Haematol Imaging haemopoietic stem cells and microenvironment dynamics through transplantation. 7(3):e259-e269 Williams KM, Chakrabarty JH
- Leukemia Pharmacological activation of nitric oxide signaling promotes human hematopoietic stem cell homing and engraftment. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0787-z. Xu D, Yang M, Capitano M, Guo B, Liu S, Wan J, Broxmeyer HE, Huang X
- Leukemia Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15R138C knock-in mice. 34(3):882-894 Tatsumi G, Kawahara M, Imai T, Nishishita-Asai A, Nishida A, Inatomi O, Yokoyama A, Kakuta Y, Kito K, Andoh A
- Leukemia HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. 34(3):909-913 Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, Xiao X, Jiang Y, Li Q, Zhang H, Lu W, Lyu C, Jiang Y, Meng J, Zhao M
- Leukemia PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. 34(3):932-937 Tumino N, Besi F, Di Pace AL, Mariotti FR, Merli P, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P
ITP
- Br J Haematol No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study. Br J Haematol. 2020 Mar 10. doi: 10.1111/bjh.16561. Lafaurie M, Baricault B, Soler V, Cassagne M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G
- Br J Haematol Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol. 2020 Mar 4. doi: 10.1111/bjh.16448. Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE)
- Haematologica Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. 105(3):e129-e132 Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, Zehnder JL